close
MENU
Guest Opinion
4 mins to read

NZ medicinal cannabis sector doesn't deserve criticism

OPINION: Celebrate the new sector, says Helius Therapeutics CEO.

Helius CEO Carmen Doran.

Carmen Doran Sat, 09 Jul 2022

The latest Ministry of Health data on medicinal cannabis uptake paints a positive picture. This comes despite ongoing criticism on the availability of local products, price, and doctors’ willingness to prescribe.

Yes, challenges around access continue, but New Zealand’s newest industry is making

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace
NZ Aviation News

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Aviation News - Monthly

NZ$14.95 / monthly

Already have an account? Login
Carmen Doran Sat, 09 Jul 2022
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
NZ medicinal cannabis sector doesn't deserve criticism
Guest Opinion,
94742
true